Celerion Implements Biometric Fingerprint Technology and Marks Five-Year Anniversary with Verified Clinical Trials
Garden City, New York (PRWEB) March 14, 2017 -- Celerion was the first early stage contract research organization (CRO) to partner with Verified Clinical Trials to improve participant safety and clinical trial data. Over the last 5 years Celerion performed nearly fifty thousand verifications utilizing the VCT global clinical database registry to identify participants that are currently enrolled in other clinical studies.
Most recently Celerion implemented VCT’s biometric fingerprint technology to augment the accuracy and speed of the verifications performed at our facilities. The use of biometrics adds another layer of protection to ensure dual enrollment in clinical trials does not occur.
Our focus has always been to help our clients get their drugs to market and protect the safety and well-being of our participants. The Verified Clinical Trials database registry enhances our ability to achieve both of those objectives, said Phil Bach, Vice President, Global Clinical Research, Celerion. “Celerion and Verified Clinical Trials share the same vision of applying scientific expertise and advanced technology to ensure the safety of our participants and maintain data integrity leading to successful clinical trial outcomes.”
“Following Celerion’s lead, the majority of Phase I units across North America now utilize the VCT system everyday to protect their clinical trials. Verified Clinical Trials offers the most comprehensive and unique clinical research subject database registry to enhance the quality of both early and late stage studies globally. The system provides a level of safety to the clinical trial process that could not be attained without a solution like Verified Clinical Trials,” said Mitchell Efros, MD FACS, CEO at Verified Clinical Trials.
“By joining forces five years ago, Celerion and VCT led the way in providing a solution that maximizes detection of attempted duplicate enrollment and protocol violations. This combined effort raised awareness and utilization across all phases of clinical research highlighting the need for a research subject database in the clinical trials industry. Working with Celerion’s team over the past five years has been a pleasure” added Kerri Weingard, COO at Verified Clinical Trials.
About Celerion
Translating science into medicine, Celerion is a premier provider of early clinical research and translational clinical pharmacology sciences from their global locations in North America, Europe and Asia.
Celerion conducts First-in-Human, clinical Proof-of-Concept and patient dose response studies, cardiovascular safety and clinical pharmacology research supporting product labeling. With purpose-built clinic and laboratory facilities and highly automated technology, Celerion provides full study services including clinical study conduct, data management and biometrics, PK/PD analysis, bioanalytical services, medical writing, and regulatory and drug development program management. For more information please visit Celerion.
About Verified Clinical Trials
Verified Clinical Trials is a forward thinking company developed by experts active in the clinical research community to proactively improve research subject safety and data quality in clinical research trials. Verified Clinical Trials defines itself as the world’s leader in the field of database registries in clinical trial research. Verified Clinical Trials is the only clinical research database registry designed specifically to enhance the quality of both early and late phase trials and has the scalability to reach all sites nationally as well as on a global level. Verified Clinical Trials offers numerous other value added services to the clinical research site, CRO, and Pharmaceutical Sponsor, that prove invaluable with regards to financial and legal issues and liabilities. For more information, visit http://www.verifiedclinicaltrials.com.
Mitchell Efros, Verified Clinical Trials, http://www.verifiedclinicaltrials.com, +1 516 469-3196, [email protected]
Share this article